Calvin Sandra
SEC CIK 1882909 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| TVTX | Travere Therapeutics, Inc. | VP, CAO, Corp Ctrl | 47.7K | — | $6.30M | 31 | 2022-01-24 | 2026-09-15 |
Most active insiders at TVTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Dube Eric M | CEO, Dir | — | $41.35M |
| 2 | Heerma Peter | EVP, Chief COMMERCIAL Off | — | $18.97M |
| 3 | ROTE WILLIAM E. | Chief Research Off | — | $16.43M |
| 4 | REED ELIZABETH E | CLO, GC | — | $7.02M |
| 5 | Inrig Jula | EVP, CMO, Head of R, D | — | $5.16M |
| 6 | Cline Christopher R. | CFO | — | $4.64M |
| 7 | Calvin Sandra | SVP, CAO | — | $4.19M |
| 8 | Baynes Roy D. | Dir | — | $2.55M |
| 9 | Meckler Jeffrey A | Dir | — | $1.71M |
| 10 | Coughlin Timothy | Dir | — | $1.27M |
Transactions 31
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-09-17 21:29 | 2026-09-15 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | M - OptEx | $24.19 | +5,375 | 47.7K | +13% | +$130.0K |
| DMT | 2026-09-17 21:29 | 2026-09-15 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | S - Sale+OE | $62.33 | -5,375 | 42.4K | -11% | -$335.0K |
| DMT | 2026-04-16 16:05 | 2026-04-14 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | M - OptEx | $16.05 | +15.2K | 64.3K | +31% | +$244.8K |
| DT | 2026-04-16 16:05 | 2026-04-14 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | S - Sale+OE | $41.07 | -22.0K | 42.4K | -34% | -$902.6K |
| D | 2026-02-03 | 2026-01-31 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | A - Grant | $0.00 | +15.2K | 53.4K | +40% | $0 |
| D | 2026-02-03 | 2026-02-03 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | S - Sale | $32.12 | -4,333 | 49.1K | -8% | -$139.2K |
| 2025-12-29 | 2025-12-24 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | S - Sale | $40.00 | -7,402 | 38.2K | -16% | -$296.1K | |
| 2025-12-16 | 2025-12-15 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | S - Sale | $36.00 | -2,910 | 45.6K | -6% | -$104.8K | |
| DM | 2025-11-06 | 2025-11-04 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | M - OptEx | $24.02 | +61.2K | 109.4K | +127% | +$1.47M |
| D | 2025-11-06 | 2025-11-04 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | S - Sale+OE | $36.00 | -67.1K | 48.5K | -58% | -$2.42M |
| DM | 2025-02-12 | 2025-02-11 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | M - OptEx | $16.63 | +45.0K | 73.7K | +157% | +$748.2K |
| DM | 2025-02-12 | 2025-02-11 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | S - Sale+OE | $25.00 | -54.2K | 63.7K | -46% | -$1.36M |
| D | 2025-02-04 | 2025-01-31 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | A - Grant | $0.00 | +13.0K | 67.0K | +24% | $0 |
| D | 2025-02-04 | 2025-02-03 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | S - Sale | $20.12 | -3,348 | 63.7K | -5% | -$67.4K |
| 2025-01-23 | 2025-01-22 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | S - Sale | $18.94 | -925 | 54.0K | -2% | -$17.5K | |
| D | 2024-12-27 | 2024-12-26 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | M - OptEx | $12.67 | +15.0K | 69.9K | +27% | +$190.1K |
| D | 2024-12-27 | 2024-12-26 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | S - Sale+OE | $17.22 | -15.0K | 54.9K | -21% | -$258.3K |
| D | 2024-11-25 | 2024-11-25 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | M - OptEx | $12.67 | +15.0K | 67.0K | +29% | +$190.1K |
| D | 2024-11-25 | 2024-11-25 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | S - Sale+OE | $18.30 | -12.1K | 54.9K | -18% | -$221.2K |
| DM | 2024-02-02 | 2024-01-31 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | A - Grant | $0.00 | +13.5K | 54.8K | +33% | $0 |
| D | 2024-02-02 | 2024-02-01 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | S - Sale | $8.53 | -2,820 | 52.0K | -5% | -$24.1K |
| 2024-01-25 | 2024-01-23 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | S - Sale | $9.07 | -910 | 41.3K | -2% | -$8,254 | |
| M | 2023-05-12 | 2023-05-10+ | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | S - Sale | $16.49 | -558 | 42.4K | -1% | -$9,200 |
| DM | 2023-02-02 | 2023-02-01+ | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | S - Sale | $21.87 | -2,031 | 42.8K | -5% | -$44.4K |
| D | 2023-02-02 | 2023-01-31 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | A - Grant | $0.00 | +10.0K | 44.8K | +29% | $0 |
| M | 2023-01-26 | 2023-01-24+ | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | S - Sale | $21.85 | -1,097 | 34.8K | -3% | -$24.0K |
| 2022-09-15 | 2022-09-13 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | S - Sale | $28.00 | -349 | 35.9K | -1.0% | -$9,772 | |
| M | 2022-05-12 | 2022-05-10+ | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, CAO | S - Sale | $21.72 | -881 | 35.7K | -2% | -$19.1K |
| D | 2022-02-02 | 2022-01-31 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | VP, CAO, Corp Ctrl | A - Grant | $0.00 | +8,750 | 37.4K | +31% | $0 |
| D | 2022-02-02 | 2022-01-31 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | VP, CAO, Corp Ctrl | S - Sale | $26.51 | -798 | 36.6K | -2% | -$21.2K |
| 2022-01-26 | 2022-01-24 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | VP, CAO, Corp Ctrl | S - Sale | $24.58 | -934 | 28.7K | -3% | -$23.0K |
Purchase Sale Sale after option exercise All abbreviations